BRPI0812040A2 - Indicações para terapia de anti-il-i-beta - Google Patents

Indicações para terapia de anti-il-i-beta

Info

Publication number
BRPI0812040A2
BRPI0812040A2 BRPI0812040-4A2A BRPI0812040A BRPI0812040A2 BR PI0812040 A2 BRPI0812040 A2 BR PI0812040A2 BR PI0812040 A BRPI0812040 A BR PI0812040A BR PI0812040 A2 BRPI0812040 A2 BR PI0812040A2
Authority
BR
Brazil
Prior art keywords
indications
beta therapy
beta
therapy
Prior art date
Application number
BRPI0812040-4A2A
Other languages
English (en)
Inventor
Hermann Gram
Thomas Jung
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0812040A2 publication Critical patent/BRPI0812040A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
BRPI0812040-4A2A 2007-05-29 2008-05-28 Indicações para terapia de anti-il-i-beta BRPI0812040A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109084 2007-05-29
PCT/EP2008/056520 WO2008145664A1 (en) 2007-05-29 2008-05-28 New indications for anti- il-i-beta therapy

Publications (1)

Publication Number Publication Date
BRPI0812040A2 true BRPI0812040A2 (pt) 2014-10-21

Family

ID=38626983

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812040-4A2A BRPI0812040A2 (pt) 2007-05-29 2008-05-28 Indicações para terapia de anti-il-i-beta

Country Status (11)

Country Link
US (7) US8282922B2 (pt)
EP (5) EP2468302A1 (pt)
JP (6) JP2010528086A (pt)
KR (7) KR20190025056A (pt)
CN (2) CN101678104A (pt)
AU (1) AU2008257520B2 (pt)
BR (1) BRPI0812040A2 (pt)
CA (7) CA2947947C (pt)
MX (1) MX2009012948A (pt)
RU (3) RU2009148597A (pt)
WO (1) WO2008145664A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041590T2 (hu) 2010-07-29 2019-05-28 Eleven Biotherapeutics Inc Kiméra IL-1 receptor I agonisták és antagonisták
CA2808185A1 (en) * 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
RU2013115927A (ru) 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
CN103059136A (zh) * 2012-12-24 2013-04-24 浙江大学 抗中华鳖IL-1β多克隆抗体的制备及在检测中的应用
EP2968468B1 (en) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
JP6456015B2 (ja) * 2013-07-19 2019-01-23 国立大学法人三重大学 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2021150266A1 (en) * 2020-01-21 2021-07-29 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
CA2165919A1 (en) 1994-12-26 1996-06-27 Koichi Katsuyama Agents for inhibiting the production of il-1.beta. and the release of tnf.
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP1282435A2 (en) * 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
DE60140201D1 (en) 2000-11-07 2009-11-26 Novartis Ag Indolylmaleimidderivative als proteinkinase-c-inhibitoren
IL162734A0 (en) 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
RS20050008A (en) 2002-07-08 2007-06-04 Pliva-Istraživački Institut D.O.O., New compounds,compositions and methods for treatment of inflammatory diseases and conditions
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
KR20050084224A (ko) 2002-12-09 2005-08-26 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 야누스 티로신 키나제 3을 선택적으로 저해하는 방법
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2005066156A1 (en) 2004-01-12 2005-07-21 Cytopia Research Pty Ltd Selective kinase inhibitors
JP4989456B2 (ja) 2004-02-26 2012-08-01 ベイラー リサーチ インスティテュート 関節炎の全身処置のための組成物および方法
WO2005117945A1 (en) * 2004-06-04 2005-12-15 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
MX2007016032A (es) * 2005-06-21 2008-03-10 Xoma Technology Ltd Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
EP1940880A2 (en) * 2005-10-14 2008-07-09 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
CN102861332A (zh) * 2005-10-26 2013-01-09 诺瓦提斯公司 IL-1β化合物的新用途
EP3124045A3 (en) * 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases

Also Published As

Publication number Publication date
CA2993565C (en) 2019-04-02
JP2016183187A (ja) 2016-10-20
US10968272B2 (en) 2021-04-06
JP6454098B2 (ja) 2019-01-16
CA3080328A1 (en) 2008-12-04
WO2008145664A1 (en) 2008-12-04
JP2020105220A (ja) 2020-07-09
EP2152308A1 (en) 2010-02-17
JP2010528086A (ja) 2010-08-19
EP4177268A2 (en) 2023-05-10
JP7069242B2 (ja) 2022-05-17
CA3030662C (en) 2020-06-30
JP2022093640A (ja) 2022-06-23
EP4177268A3 (en) 2023-05-24
JP2018104462A (ja) 2018-07-05
KR20100022082A (ko) 2010-02-26
KR20180032687A (ko) 2018-03-30
US20170073411A1 (en) 2017-03-16
AU2008257520B2 (en) 2012-04-05
US9168298B2 (en) 2015-10-27
CA2687499C (en) 2017-11-28
US20120321642A1 (en) 2012-12-20
AU2008257520A1 (en) 2008-12-04
KR102606597B1 (ko) 2023-11-29
CN104873972A (zh) 2015-09-02
CA3156905A1 (en) 2008-12-04
RU2698208C2 (ru) 2019-08-23
EP2468301A1 (en) 2012-06-27
US9534047B2 (en) 2017-01-03
US20100166750A1 (en) 2010-07-01
JP6685339B2 (ja) 2020-04-22
US20190002554A1 (en) 2019-01-03
US8524667B2 (en) 2013-09-03
US10106604B2 (en) 2018-10-23
CA2947947C (en) 2018-03-06
MX2009012948A (es) 2009-12-14
CA2947947A1 (en) 2008-12-04
CA2687499A1 (en) 2008-12-04
US20160002328A1 (en) 2016-01-07
KR20210047376A (ko) 2021-04-29
KR20220050240A (ko) 2022-04-22
JP7459166B2 (ja) 2024-04-01
RU2014101207A (ru) 2015-07-20
CA3030662A1 (en) 2008-12-04
US20130309241A1 (en) 2013-11-21
CA3080328C (en) 2022-06-21
JP2014205706A (ja) 2014-10-30
CN101678104A (zh) 2010-03-24
EP2468302A1 (en) 2012-06-27
RU2009148597A (ru) 2011-07-10
CA2993565A1 (en) 2008-12-04
CA3156905C (en) 2023-11-07
EP3406263A1 (en) 2018-11-28
RU2019125748A (ru) 2021-02-15
US20210179705A1 (en) 2021-06-17
RU2019125748A3 (pt) 2022-02-11
KR20160017119A (ko) 2016-02-15
US8282922B2 (en) 2012-10-09
RU2698208C9 (ru) 2019-10-11
CA3213888A1 (en) 2008-12-04
KR101591533B1 (ko) 2016-02-03
KR20230130763A (ko) 2023-09-12
KR20190025056A (ko) 2019-03-08

Similar Documents

Publication Publication Date Title
BRPI0813497A2 (pt) Tampão antisséptico com cobertura para linha
BRPI0818380A2 (pt) Combinação de herbicida-protetor
PA8805201A1 (es) Piperidinas heteroaril-sustituidas
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
AT505058A3 (de) Türschliesssystem
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802
BRPI0807984A2 (pt) Unidade de distribuição
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI0812105A2 (pt) Neramexano para o tratamento de nistagmo
ES1064720Y (es) Guia para persiana
ES1064958Y (es) Soporte para mechero
ES1065457Y (es) Dispositivo de amortiguacion para quads
ES1065835Y (es) Caperuza para cetreria
ES1063735Y (es) Testero para persiana
DE112007003477A5 (de) Schutzgerät
DE112007003228A5 (de) Temperiervorrichtung
ES1062659Y (es) Estructura para cubiertas
AT9563U3 (de) Wirbelsäulenzuggurtung
ES1065168Y (es) Soporte para biberon
AT504425B1 (de) Portioniersteuerung
ES1065263Y (es) Captafaros para bionda
ES1066482Y (es) Pieza constructiva para paramento
ES1063779Y (es) Pallon para gaitas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]